We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geogr... Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada. Show more
Ask ADVFN Intelligence (AI)
Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative Canada NewsWire TORONTO, Dec. 19, 2024 Twenty Canadian Fellows Participate in the Inaugural...
— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted...
Six Late-Stage Programs with Peak Revenue Potential of $10B - $20B1 Poised to Deliver Sustainable Growth Expected Phase 3 Data Readouts in 2025 for Oveporexton (TAK-861), Zasocitinib (TAK-279...
− Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and...
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several...
Un nouveau sondage souligne l'importance de prioriser la santé mentale des Canadiens atteints de MII Canada NewsWire TORONTO, le 4 nov. 2024 Environ 300 000 Canadiens souffrent...
Umsatzwachstum von +13,4 % zu aktuellen Wechselkursen (AER); +5,0 % zu konstanten Wechselkursen (CER) Getrieben durch die kontinuierliche Weiterentwicklung von Wachstums- und...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.39 | -2.89103039288 | 13.49 | 13.49 | 12.98 | 1512411 | 13.22880998 | DR |
| 4 | -0.23 | -1.72543135784 | 13.33 | 14.04 | 12.98 | 1557763 | 13.52755573 | DR |
| 12 | -1.52 | -10.3967168263 | 14.62 | 14.67 | 12.98 | 1688777 | 13.80390368 | DR |
| 26 | 0.48 | 3.80348652932 | 12.62 | 15.08 | 12.575 | 1927789 | 13.92829844 | DR |
| 52 | -0.73 | -5.27838033261 | 13.83 | 15.08 | 12.575 | 1818722 | 13.9514216 | DR |
| 156 | -0.56 | -4.09956076135 | 13.66 | 17.15 | 12.28 | 2267300 | 14.52888734 | DR |
| 260 | -7.19 | -35.4361754559 | 20.29 | 20.6 | 12.28 | 2151578 | 15.4430807 | DR |
Monksdream
9 months ago
Boing x 2
2 years ago
Phosphene
4 years ago
Phosphene
4 years ago
Phosphene
4 years ago
rising
7 years ago
rising
7 years ago
trendmkr
9 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
